Stay updated on Rapid Test & Treat Dolutegravir Plus Lamivudine Clinical Trial

Sign up to get notified when there's something new on the Rapid Test & Treat Dolutegravir Plus Lamivudine Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Rapid Test & Treat Dolutegravir Plus Lamivudine Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T20:21:19.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents the completion of a Phase 3b multi-center, open-label, single-arm, 52-week study evaluating the feasibility, efficacy, and safety of a rapid Test and Treat intervention in newly diagnosed HIV-1 infected adults using a fixed dose combination of Dolutegravir Plus Lamivudine as a first-line regimen.
    Difference
    0.1%
    Check dated 2024-06-06T14:15:22.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed eligibility criteria for study participants, including requirements for understanding and complying with protocol, health conditions, and prior treatments. The new criteria specify inclusion and exclusion conditions, such as age, health status, and specific medical history.
    Difference
    42%
    Check dated 2024-05-22T20:29:15.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:36:47.000Z thumbnail image

Stay in the know with updates to Rapid Test & Treat Dolutegravir Plus Lamivudine Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Rapid Test & Treat Dolutegravir Plus Lamivudine Clinical Trial page.